Sponsored Links
| FREEDOM-M Trial Of Oral Treprostinil In Pulmonary Arterial Hypertension Meets Primary Endpoint |
 |
 |
 |
| Medical News - Hypertension | |||
|
United Therapeutics Corporation (NASDAQ: UTHR) announced the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH)... Read more: Hypertension News From Medical News Today
|